Abstract
Radiotheranostics is a radionuclide therapy based on the results of molecular imaging with various radiopharmaceuticals, allowing in vivo whole body imaging (SPECT, PET), and then systemically and at the same time selectively acting on pathological metabolic processes caused by a pathological process. In recent years, thanks to advances in the development of nuclear medicine (an increase in the number of cyclotrons, SPECT / CT and PET / CT in medical institutions) and, particularly, novel radiopharmaceuticals — in the world, radiotheranostics is developing very rapidly. The emergence of new radioligands labelled by 177 Lu, 131 I, 225 Ac and other radioisotopes in the world have initiated a large number of clinical trials of radioligand therapy of neuroendocrine and chromaffin tumors, prostate cancer, etc. Radiotherapy as a new and very promising direction of nuclear medicine and it is perfectly integrated into modern diagnostic algorithms in the field of endocrinology and oncology. Methods of intraoperative radionavigation make it possible to increase the efficiency and safety of surgical methods, external beam radiation therapy, and brachytherapy. In my opinion, the future of personalized medicine will be predominantly determined by the integration of radiotherapy, multimodal imaging, intraoperative navigation and existing/new methods of diagnosis and treatment, in combination with applied genomic and post-genomic technologies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.